Skip to main content

Table 3 FDA-approved chemotherapy and immunotherapy combination

From: Combination strategies to maximize the benefits of cancer immunotherapy

Cancer Line of therapy Chemotherapy Immunotherapy Clinical benefit Statistics Trial name and reference
NSCLC-non-squamous Metastatic, first-line Pemetrexed + platinum Pembrolizumab OS at 12 Mos: 69.2% versus 49.4% HR 0.49; 95% CI 0.38–0.64; P < 0.001 KEYNOTE-189 [50],
NSCLC-non-squamous Metastatic, first-line Carboplatin + nabpaclitaxel Atezolizumab OS: 18.6 versus 13.9 Mos HR 0·79; 95% CI 0·64–0·98; p = 0·033 IMpower 130, [51]
NSCLC-non-squamous Metastatic, first-line Carboplatin + paclitaxel + bevacizumab Atezolizumab OS: 19.2 versus 14.7 mo HR 0.78; 95% CI 0.64 to 0.96; P = 0.02 IMpower 150, [297]
NSCLC Metastatic, first-line Platinum doublet Nivolumab + ipilimumab OS 15.6 versus 10.9 m; HR 0.66; 95% CI 0.55–0.80; P = 0.00065 CheckMate-9LA, [299]
NSCLC-squamous Metastatic, first-line Carboplatin + paclitaxel/ nabpaclitaxel Pembrolizumab OS: 15.9 versus 11.3 months HR 0.64; 95% CI 0.49 to 0.85; P < 0.001 KEYNOTE-407, [52]
SCLC Extensive stage, first-line Carboplatin + etoposide Atezolizumab concurrent and maintenance OS: 12.3 versus 10.3 m HR 0.70; 95% CI 0.54–0.91; P = 0.007 IMpower133, [53]
SCLC Extensive stage, first-line Carboplatin + etoposide Durvalumab OS: 12.9 versus 10.5 months HR 0·73 (95% CI 0·59–0·91; p = 0·0047 CASPIAN, [54]
Breast triple negative Metastatic, first-line nabpaclitaxel Atezolizumab OS: 25.0 versus 15.5 months (PD-L1( +) HR 0.62; 95% CI 0.45–0.86 IMpassion 130, [55]
Breast triple negative Metastatic, first-line Nabpaclitaxel or paclitaxel or carbpolatin + Gemcitabine Pembrolizumab PFS (CPS > 10) 9.7 versus 5.6 m: HR 0·65, 95% CI 0·49–0·86; one-sided p = 0·0012 KEYNOTE 355, [56]
Bladder cancer Metastatic, first-line maintenance Gemcitabine + cisplatin/carboplatin Avelumab OS: 21.1 versus 14.3 Mo HR 0.69; 95% CI 0.56 to 0.86; P = 0.001 JAVELIN Bladder 100, [58]
Head and Neck Cancer Metastatic first-line Platinum + 5-FU or platinum + 5-FU + cetuximab Pembrolizumab OS: 13·6 versus 10·4 (CPS ≥ 1) HR 0·65; 95% CI 0·53–0·80; p < 0·0001 KEYNOTE-048, [57]